Eli Lilly扩大了印度制造业计划1B美元,以增加全球Mounjaro的供应,并通过当地伙伴关系扩大准入。 Eli Lilly expands $1B India manufacturing plan to boost global Mounjaro supply and expand access via local partnerships.

Eli Lilly正在扩大其对印度合同制造的10亿美元承诺,目的是使印度成为包括Mounjaro治疗肥胖症在内的毒品的全球出口枢纽,因为按价值计算,Mounjaro已成为印度最大的销售产品。 Eli Lilly is expanding its $1 billion commitment to contract manufacturing in India, aiming to position the country as a global export hub for its drugs, including the obesity treatment Mounjaro, which has become its top-selling product in India by value. 这一举动利用印度强大的制药基础设施向全世界提供药品,并计划引进新的治疗方法,如Donanemab和或forglipron等有待批准。 The move leverages India’s strong pharmaceutical infrastructure to supply medicines worldwide, with plans to introduce new treatments like donanemab and orforglipron pending approvals. 尽管Novo Nordisk的Wegovy在专利过期后面临通用竞争, 但Lilly强调Mounjaro的功效和价值定价。 Despite competition from Novo Nordisk’s Wegovy, which faces generic competition after its patent expires, Lilly emphasizes Mounjaro’s efficacy and value-based pricing. 该公司通过数字平台和与印度Cipla公司、Tata 1MG公司、Practo公司和阿波罗公司等印度公司的伙伴关系,正在扩大接入范围。 The company is broadening access through digital platforms and partnerships with Indian firms such as Cipla, Tata 1MG, Practo, and Apollo.